We were pleased to have you at the 13th iVis International Users’ Meeting.
The Meeting was focused on the CIPTA® Web application with three dedicated sessions:
- Session 1: Principles, Definitions, Settings, and Web Communication protocol
- Session 2: Customized ray-tracing ablation plans for phakic and pseudo-phakic eyes
- Session 3: Preliminary Outcomes and Live Surgery
iVis’ European Patent EP 1 649 843 relates to an intelligent control of the areal power density delivered by laser systems in corneal surgery.
We are pleased to announce the CE approval on iRes™2, our fastest 2.0Khz excimer laser, empowering the smallest 350um laser micro-spot to execute iVis proprietary full automated, real-time controlled, no-touch, cTen® surgical procedure, maximizing surgical performance and avoiding intra-operative risks.
We are pleased to announce the CE approval on CIPTA®2, the unique cloud-based software conceived for interactive ray-tracing customized corneal surgical planning
We are pleased to announce the achievement of the CE mark on SafeCross®+ medical device on May 7th, 2021.
SafeCross®+ is a riboflavin ophthalmic solution, patented by iVis Technologies, granting high cross-linking efficiency in poor oxygen environment.
The 4D Suite™ is an integrated ensemble of hardware and software devices.
We are pleased to announce you that iVis 11th International Users’ meeting will be held in the form of a Webinar.
We are pleased to inform you that, on the 21st of February 2020, iVis Technologies received the CE Certification (awarded in compliance with the MDD 93/42/EEC European directive) for the commercialization of SafeCross™ medical device.
